Abstract
PurposeTo investigate the longitudinal changes in neovascularization of the retinal elsewhere (NVE) size on optical coherence tomography angiography (OCTA) in proliferative diabetic retinopathy (PDR) treated by panretinal photocoagulation (PRP) alone or by single intravitreal conbercept injection plus PRP.MethodsA prospective pilot study. Forty-four PDR eyes with NVE confirmed by fundus fluorescein angiography (FFA) and OCTA were included. They were assigned to receive PRP alone (PRP group) or intravitreal conbercept injection plus PRP (combination group). Ophthalmic examinations, including BCVA and OCTA to measure the NVE size, were performed at baseline before each PRP session, and at 1, 3, and 6 months.ResultsTwenty-nine eyes were included in the PRP group, and 15 eyes were included in the combination group. There was no significant difference between the two groups with respect to age, BCVA, and NVE area at baseline. In both groups, there was a significant (P < 0.05) NVE size reduction during the majority of study visits, with the reduction observed in the combination group significantly larger than that in the PRP group. No significant BCVA changes were observed in either groups, except that in the PRP group, the BCVA at 3 months was significantly improved (P < 0.05). No deaths or unexpected adverse events (AEs) were reported.ConclusionsIntravitreal conbercept plus PRP was more effective than PRP monotherapy in NVE regression. Precise quantification of the NVE area by OCTA makes it a useful tool for monitoring the response of retinal neovascular lesions to the therapy.
Highlights
Diabetic retinopathy (DR) is the leading cause of visual impairment and blindness in the working population around the world
A within-group statistically significant reduction in neovascularization of the retinal elsewhere (NVE) size compared with baseline was found during treatment in the panretinal photocoagulation (PRP) group, and the NVE size at 3 months after treatment was significantly larger (P < 0.05)
There was a statistically significant reduction in NVE size compared with baseline at all time points in the combination group
Summary
Diabetic retinopathy (DR) is the leading cause of visual impairment and blindness in the working population around the world. In China, DR is responsible for vision loss in 12.6% of diabetic patients and tends to occur in patients much younger than those in Western countries [1, 2]. As a severe stage of DR, proliferative diabetic retinopathy (PDR) poses the greatest threat to visual function due to neovascular F. Conbercept has been used in other diseases with neovascularization [11,12,13], the use of conbercept in the treatment of PDR is off-label, and there are few reports on this topic. The temporal profile of the response of retinal neovascularization to PRP alone or single-dose conbercept combined with PRP has yet to be established and should be useful for defining the comparative efficacy of different therapy choices as well as the optimal retreatment time
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
